HDV重叠感染可增加慢性乙型肝炎患者的肝细胞癌风险

于哲; 杨永平

doi:10.3969/j.issn.1001-5256.2020.04.053

HDV重叠感染可增加慢性乙型肝炎患者的肝细胞癌风险

DOI: 10.3969/j.issn.1001-5256.2020.04.053

于哲,
杨永平

1. 北京大学三〇二临床医学院
2. 解放军总医院第五医学中心肝脏肿瘤诊疗与研究中心

基金项目:

国家“十三五”科技重大专项(2018ZX10725506)；

详细信息

中图分类号: R512.62;R735.7
计量
- 文章访问数: 938
- HTML全文浏览量: 44
- PDF下载量: 488
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

Concurrent hepatitis D virus infection increases risk of hepatocellular carcinoma in patients with chronic hepatitis B

Peking University 302 Clinical Medical School

Research funding:

摘要

摘要: HDV的重叠感染可加速慢性乙型肝炎患者的肝病进程,尤其肝细胞癌(HCC)的发生风险明显增高。但HDV的致癌机制有待进一步探索,治疗方式及效果也亟待突破。综述了HDV相关HCC流行病学新特点、致病机制的新认识和诊疗进展等,对推进研发更精准的HDV检测手段、更有效的治疗药物及减少HDV相关HCC具有重要意义。
- 肝炎病毒 /
- 乙型肝炎,慢性 /
- 重叠感染
Abstract: Concurrent hepatitis D virus( HDV) infection accelerates the progression of liver disease in patients with chronic hepatitis B and particularly increases the risk of hepatocellular carcinoma( HCC). Further studies are still needed to explore the carcinogenic mechanism of HDV,related treatment methods,and their clinical effects. This article reviews the new epidemiological characteristics of HDV-related HCC,the new understanding of the pathogenic mechanism of HDV,and the advances in diagnosis and treatment,which is of great significance to promote the development of accurate HDV detection methods and effective drugs and reduce HDV-related HCC.
- hepatitis delta virus /
- hepatitis B,chronic /
- superinfection

HTML全文

参考文献(44)

[1] Polaris Observatory Collaborators. Global prevalence,treatment,and prevention of hepatitis B virus infection in 2016:A modelling study[J]. Lancet Gastroenterol Hepatol,2018,3(6):383-403.

[2] FLORES R,RUIZ-RUIZ S,SERRA P. Viroids and hepatitis delta virus[J]. Semin Liver Dis,2012,32(3):201-210.

[3] SHIRVANI-DASTGERDI E,TACKE F. Molecular interactions between hepatitis B virus and delta virus[J]. World J Virol,2015,4(2):36-41.

[4] DENY P. Hepatitis delta virus genetic variability:From genotypes I,II,III to eight major clades?[J]. Curr Top Microbiol Immunol,2006,307:151-171.

[5] GAETA GB,STROFFOLINI T,CHIARAMONTE M,et al. Chronic hepatitis D:A vanishing disease? An Italian multicenter study[J]. Hepatology,2000,32(4 Pt 1):824-827.

[6] HEIDRICH B,DETERDING K,TILLMANN HL,et al. Virological and clinical characteristics of delta hepatitis in Central Europe[J]. J Viral Hepat,2009,16(12):883-894.

[7] PATEL EU,THIO CL,BOON D,et al. Prevalence of hepatitis B and hepatitis D virus infections in the United States,2011-2016[J]. Clin Infect Dis,2019,69(4):709-712.

[8] RIZZETTO M,CIANCIO A. Epidemiology of hepatitis D[J].Semin Liver Dis,2012,32(3):211-219.

[9] HAO LJ,LI L,ZHANG YY,et al. Hepatitis D virus infection in liver tissues of patients with hepatitis B in China[J]. Chin Med J(Engl),1992,105(3):204-208.

[10] HUO TI,WU JC,LAI CR,et al. Comparison of clinico-pathological features in hepatitis B virus-associated hepatocellular carcinoma with or without hepatitis D virus superinfection[J].J Hepatol,1996,25(4):439-444.

[11] CROSS TJ,RIZZI P,HORNER M,et al. The increasing prevalence of hepatitis delta virus(HDV)infection in South London[J]. J Med Virol,2008,80(2):277-282.

[12] TOUKAN AU,ABU-EL-RUB OA,ABU-LABAN SA,et al.The epidemiology and clinical outcome of hepatitis D virus(delta)infection in Jordan[J]. Hepatology,1987,7(6):1340-1345.

[13] TAMURA I,KURIMURA O,KODA T,et al. Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection:A study from Kure,Japan[J]. J Gastroenterol Hepatol,1993,8(5):433-436.

[14] FATTOVICH G,GIUSTINA G,CHRISTENSEN E,et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis(Eurohep)[J]. Gut,2000,46(3):420-426.

[15] UZUNALIMOGˇLU O,YURDAYDIN C,CETINKAYA H,et al.Risk factors for hepatocellular carcinoma in Turkey[J]. Dig Dis Sci,2001,46(5):1022-1028.

[16] DEGˇERTEKIN H,YALIN K,YAKUT M. The prevalence of hepatitis delta virus infection in acute and chronic liver diseases in Turkey:An analysis of clinical studies[J]. Turk J Gastroenterol,2006,17(1):25-34.

[17] ROMEO R,DEL NINNO E,RUMI M,et al. A 28-year study of the course of hepatitis delta infection:A risk factor for cirrhosis and hepatocellular carcinoma[J]. Gastroenterology,2009,136(5):1629-1638.

[18] BUTI M,HOMS M,RODRIGUEZ-FRIAS F,et al. Clinical outcome of acute and chronic hepatitis delta over time:A longterm follow-up study[J]. J Viral Hepat,2011,18(6):434-442.

[19] JI J,SUNDQUIST K,SUNDQUIST J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma[J]. J Natl Cancer Inst,2012,104(10):790-792.

[20] ROMEO R,FOGLIENI B,CASAZZA G,et al. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta[J]. PLo S One,2014,9(3):e92062.

[21] KUSHNER T,SERPER M,KAPLAN DE. Delta hepatitis within the Veterans Affairs medical system in the United States:Prevalence,risk factors,and outcomes[J]. J Hepatol,2015,63(3):586-592.

[22] AMOUGOU MA,NOAH DN,MOUNDIPA PF,et al. A prominent role of hepatitis D virus in liver cancers documented in Central Africa[J]. BMC Infect Dis,2016,16(1):647.

[23] BEGUELIN C,MORADPOUR D,SAHLI R,et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients[J].J Hepatol,2017,66(2):297-303.

[24] BRANCACCIO G,FASANO M,GROSSI A,et al. Clinical outcomes in patients with hepatitis D,cirrhosis and persistent hepatitis B virus replication,and receiving long-term tenofovir or entecavir[J]. Aliment Pharmacol Ther,2019,49(8):1071-1076.

[25] MAHALE P,AKA P,CHEN X,et al. Hepatitis D virus infection,cirrhosis and hepatocellular carcinoma in The Gambia[J]. J Viral Hepat,2019,26(6):738-749.

[26] PASCARELLA S,NEGRO F. Hepatitis D virus:An update[J].Liver Int,2011,31(1):7-21.

[27] SUREAU C,NEGRO F. The hepatitis delta virus:Replication and pathogenesis[J]. J Hepatol,2016,64(1 Suppl):s102-s116.

[28] CHOI SH,JEONG SH,HWANG SB. Large hepatitis delta antigen modulates transforming growth factor-beta signaling cascades:Implication of hepatitis delta virus-induced liver fibrosis[J]. Gastroenterology,2007,132(1):343-357.

[29] GUILHOT S,HUANG SN,XIA YP,et al. Expression of the hepatitis delta virus large and small antigens in transgenic mice[J]. J Virol,1994,68(2):1052-1058.

[30] DIAZ G,ENGLE RE,TICE A,et al. Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma[J]. Mol Cancer Res,2018,16(9):1406-1419.

[31] PHILIPP T,DURAZZO M,TRAUTWEIN C,et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3antibodies in chronic hepatitis D[J]. Lancet,1994,344(8922):578-581.

[32] WILLIAMS V,BRICHLER S,KHAN E,et al. Large hepatitis delta antigen activates STAT-3 and NF-κB via oxidative stress[J]. J Viral Hepat,2012,19(10):744-753.

[33] PARK CY,OH SH,KANG SM,et al. Hepatitis delta virus large antigen sensitizes to TNF-alpha-induced NF-kappaB signaling[J]. Mol Cells,2009,28(1):49-55.

[34] WARIS G,HUH KW,SIDDIQUI A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress[J].Mol Cell Biol,2001,21(22):7721-7730.

[35] BENEGIAMO G,VINCIGUERRA M,GUARNIERI V,et al. Hepatitis delta virus induces specific DNA methylation processes in Huh-7liver cancer cells[J]. FEBS Lett,2013,587(9):1424-1428.

[36] LIAO FT,LEE YJ,KO JL,et al. Hepatitis delta virus epigenetically enhances clusterin expression via histone acetylation in human hepatocellular carcinoma cells[J]. J Gen Virol,2009,90(Pt 5):1124-1134.

[37] LAU SH,SHAM JS,XIE D,et al. Clusterin plays an important role in hepatocellular carcinoma metastasis[J]. Oncogene,2006,25(8):1242-1250.

[38] ZHANG Q,MATSUURA K,KLEINER DE,et al. Analysis of long noncoding RNA expression in hepatocellular carcinoma of different viral etiology[J]. J Transl Med,2016,14(1):328.

[39] SORIANO V,VISPO E,SIERRA-ENGUITA R,et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients[J]. AIDS,2014,28(16):2389-2394.

[40] LE GAL F,BRICHLER S,SAHLI R,et al. First international external quality assessment for hepatitis delta virus RNA quantification in plasma[J]. Hepatology,2016,64(5):1483-1494.

[41] HEIDRICH B,YURDAYDIN C,KABAAM G,et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta[J]. Hepatology,2014,60(1):87-97.

[42] ETZION O,HAMID S,LURIE Y,et al. End of study results from LIMT HDV study:36%durable virologic response at 24weeks post-treatment with pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection[J]. J Hepatology,2019,70:e32.

[43] ELAZAR M,GLENN JS. Emerging concepts for the treatment of hepatitis delta[J]. Curr Opin Virol,2017,24:55-59.

[44] LEONG PL,ANDREWS GA,JOHNSON DE,et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth[J]. Proc Natl Acad Sci U S A,2003,100(7):4138-4143.

施引文献

资源附件(0)

访问统计